Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Borget

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.
Endocrine-Related Cancer|December 25, 2010
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin levelC Nascimento, I Borget, A Al Ghuzlan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 16, 2016
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid CancerLivia Lamartina, S Ippolito, M Danis, et al.
BMC Cancer|November 8, 2015
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)C Raynaud, L Greillier, J Mazieres, et al.
Endocrine|March 10, 2020
Locally unresectable differentiated thyroid cancer: outcomes and perspectivesL Lamartina, Y Godbert, C Nascimento, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2011
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patientsM Brassard, I Borget, A Edet-Sanson, et al.
Endocrine-Related Cancer|March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinomaJ Hadoux, D Malka, D Planchard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2015
Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-upC Lepoutre-Lussey, C Caramella, F Bidault, et al.
ESMO Open|March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RETJ Hadoux, J Hernando, K H Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2015
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) studyR Libé, I Borget, C L Ronchi, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.
Endocrine-Related Cancer|December 25, 2010
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin levelC Nascimento, I Borget, A Al Ghuzlan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 16, 2016
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid CancerLivia Lamartina, S Ippolito, M Danis, et al.
BMC Cancer|November 8, 2015
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)C Raynaud, L Greillier, J Mazieres, et al.
Endocrine|March 10, 2020
Locally unresectable differentiated thyroid cancer: outcomes and perspectivesL Lamartina, Y Godbert, C Nascimento, et al.
The Journal of Clinical Endocrinology and Metabolism|March 11, 2011
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patientsM Brassard, I Borget, A Edet-Sanson, et al.
Endocrine-Related Cancer|March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinomaJ Hadoux, D Malka, D Planchard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 14, 2015
Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-upC Lepoutre-Lussey, C Caramella, F Bidault, et al.
ESMO Open|March 4, 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RETJ Hadoux, J Hernando, K H Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2015
Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) studyR Libé, I Borget, C L Ronchi, et al.
Pageof 4